Literature DB >> 9576035

[Radiotherapy in surgical and nonsurgical patients. Therapy expectations, quality of life and physician assessment].

K Wagner1, M Koller, A Keil, D Trott, R Engenhart-Cabillic, R Pfab, W Lorenz.   

Abstract

The present study investigates patients' expectations toward radiotherapy and their associations to quality of life and physician judgements. Fifty-five patients with tumors of different sites (30 with previous tumor-related surgery, 25 without surgery) admitted to the department of radiotherapy filled out a standardized questionnaire (EORTC QLQ-C30, PLC by Siegrist et al., therapy-related expectations and success) before and after inpatient radiotherapy. The corresponding physician ratings were collected. Fifty-eight percent of the patients expected the therapeutic goal "healing", whereas from the physician's standpoint this was realistic in only 7% of cases. The specific radiotherapy-related expectations "tumor control" and "pain relief" reached almost the same levels in patients and physician (71% vs 71% and 40% vs 44%). Patients with healing expectancy reported higher quality of life at the beginning of the therapy (53.4% vs 39.9%); patients expecting pain relief reported lower quality of life (37.1% vs 54.5%). Surgical patients who had been operated on within the past year (n = 18) showed a particularly high healing expectancy (83%), whereas patients whose operation dated back more than 1 year focused on pain relief as therapeutic goal (83%). The surgeon, as the primary contact person for patients, can influence patients' therapy-related expectations. In explaining the overall therapeutic strategy, surgeons should also mention the scope and limits of adjuvant therapies.

Entities:  

Mesh:

Year:  1998        PMID: 9576035     DOI: 10.1007/s001040050407

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  1 in total

Review 1.  Quality of life: a deconstruction for clinicians.

Authors:  Michael Koller; Wilfried Lorenz
Journal:  J R Soc Med       Date:  2002-10       Impact factor: 18.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.